For most pre-commercial biotech companies seeking FDA approval, manufacturing readiness is usually the last step to check by FDA before its making decision on whether to approve the underlining drug/biological product/vaccine, so in this sense June 2023 is more than achievable since UK MHRA has just checked the readiness item (module).
By the time when MAA is submitted, it's also possible MHRA has reviewed most, if not all contents of MAA, so it is certainly possible the approval may come earlier than a lot of folks would expect.
Regardless, it becomes easier by the days/months to hold and/or add more shares as we have done just that already for years, if not a decade.
Bullish